-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Atypical CML-Diagnosis and Treatment

Program: Education Program
Session: How Do We Tackle Remaining Clinical Challenges in CML?
Hematology Disease Topics & Pathways:
Biological therapies, MPN, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Sunday, December 10, 2023, 4:30 PM-5:45 PM

Massimo Breccia

Department of Translational and Precision Medicine, Hematology-Sapienza University, Rome, Italy

Disclosures: Breccia: AOP: Honoraria; Incyte: Honoraria; Pfizer: Honoraria; BMS: Honoraria; AbbVie: Honoraria; Novartis: Honoraria.

OffLabel Disclosure: Ruxolitinib, trametinib, venetoclax, itacitinib

See more of: How Do We Tackle Remaining Clinical Challenges in CML?
See more of: Education Program
<< Previous Presentation | Next Presentation